Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer

Authors

  • Hassanabbas Z. Mohamedali Division of General Internal Medicine & Clinical Epidemiology, University Health Network, University of Toronto, Toronto, ON
  • Henriette Breunis Division of General Internal Medicine & Clinical Epidemiology, University Health Network, University of Toronto, Toronto, ON
  • Narhari Timilshina Division of General Internal Medicine & Clinical Epidemiology, University Health Network, University of Toronto, Toronto, ON
  • Shabbir M.H. Alibhai Geriatric Program, Toronto Rehabilitation Institute; Departments of Medicine and Health Policy, Management and Evaluation, University of Toronto, Toronto, ON

DOI:

https://doi.org/10.5489/cuaj.556

Abstract

Objective: To investigate the effects of androgen deprivation therapy
(ADT) on blood glucose and cholesterol over 12 months in a
prospective matched cohort study.

Methods: English-speaking patients with non-metastatic prostate
cancer attending the Princess Margaret Hospital were invited to
participate in this study. Patients were divided into two cohorts:
ADT users and controls. Androgen deprivation therapy users were
frequency matched to controls on age, education and body mass
index (BMI). The study consisted of two visits. Sociodemographic
and clinical information, medication use, physical fitness, height
and weight were collected before initiation of ADT. Twelve months
later, fasting morning blood work was obtained to measure plasma
glucose, total cholesterol, high-density lipoprotein (HDL), low-density
lipoprotein (LDL) and triglycerides. Statistical analyses included
univariate and multivariable linear regression.

Results: We recruited 75 patients (mean age 68.9), 38 of whom
were undergoing ADT. Twelve patients with prior diabetes and 29
patients taking cholesterol-lowering medication at baseline were
excluded from the glucose and cholesterol analysis, respectively.
In adjusted analyses, ADT users had a significantly higher glucose
level compared to controls (5.88 vs. 5.52 mmol/L, p = 0.024).
Overall, ADT users had higher levels of total cholesterol, HDL,
LDL, and triglycerides than controls, although none of the differences
reached statistical significance.

Conclusion: One year of ADT use is associated with elevated fasting
glucose levels and may increase all lipid fractions in men with
prostate cancer.

Downloads

Download data is not yet available.

Author Biographies

Hassanabbas Z. Mohamedali, Division of General Internal Medicine & Clinical Epidemiology, University Health Network, University of Toronto, Toronto, ON

Henriette Breunis, Division of General Internal Medicine & Clinical Epidemiology, University Health Network, University of Toronto, Toronto, ON

Narhari Timilshina, Division of General Internal Medicine & Clinical Epidemiology, University Health Network, University of Toronto, Toronto, ON

Shabbir M.H. Alibhai, Geriatric Program, Toronto Rehabilitation Institute; Departments of Medicine and Health Policy, Management and Evaluation, University of Toronto, Toronto, ON

Downloads

How to Cite

Mohamedali, H. Z., Breunis, H., Timilshina, N., & Alibhai, S. M. (2013). Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer. Canadian Urological Association Journal, 5(1), 28–33. https://doi.org/10.5489/cuaj.556

Issue

Vol. 5 No. 1 (2011): February

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.